Key stats
Market capitalization
17.169MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−5.17USD
About Aprea Therapeutics, Inc
ISIN
US03836J2015
Sector
Health Technology
Industry
Pharmaceuticals: Major
Website
aprea.com
CEO
Oren Gilad
Headquarters
Doylestown
Founded
2002
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the provision of cancer therapeutics. It is involved in the development and commercialization of novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wen Jie Bao in 2002 and is headquartered in Doylestown, PA.
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
0
Revenue
0